Stephens Investment Management Group LLC Buys 124,264 Shares of Simulations Plus, Inc. $SLP

Stephens Investment Management Group LLC raised its position in Simulations Plus, Inc. (NASDAQ:SLP) by 46.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 392,840 shares of the technology company’s stock after acquiring an additional 124,264 shares during the period. Stephens Investment Management Group LLC owned approximately 1.95% of Simulations Plus worth $5,920,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of SLP. Royal Bank of Canada increased its position in shares of Simulations Plus by 26.6% during the first quarter. Royal Bank of Canada now owns 114,885 shares of the technology company’s stock worth $2,817,000 after purchasing an additional 24,132 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Simulations Plus by 4.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,493 shares of the technology company’s stock valued at $233,000 after buying an additional 390 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Simulations Plus in the first quarter valued at about $255,000. Woodline Partners LP boosted its holdings in Simulations Plus by 32.1% in the first quarter. Woodline Partners LP now owns 13,239 shares of the technology company’s stock worth $325,000 after acquiring an additional 3,220 shares in the last quarter. Finally, North Star Investment Management Corp. boosted its holdings in Simulations Plus by 7.3% in the second quarter. North Star Investment Management Corp. now owns 56,875 shares of the technology company’s stock worth $992,000 after acquiring an additional 3,875 shares in the last quarter. 78.08% of the stock is owned by hedge funds and other institutional investors.

Simulations Plus Price Performance

NASDAQ:SLP opened at $20.33 on Friday. The company’s fifty day moving average price is $18.52 and its 200-day moving average price is $16.33. Simulations Plus, Inc. has a 1-year low of $12.39 and a 1-year high of $37.67. The firm has a market capitalization of $409.65 million, a P/E ratio of -6.35 and a beta of 1.09.

Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings results on Thursday, January 8th. The technology company reported $0.13 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.05). The business had revenue of $18.42 million during the quarter, compared to analysts’ expectations of $18.05 million. Simulations Plus had a negative net margin of 81.66% and a positive return on equity of 14.02%. During the same period in the previous year, the company posted $0.17 earnings per share. Equities analysts anticipate that Simulations Plus, Inc. will post 1.09 EPS for the current fiscal year.

Analyst Ratings Changes

SLP has been the topic of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Simulations Plus in a report on Wednesday, October 8th. Zacks Research upgraded shares of Simulations Plus from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 28th. KeyCorp reaffirmed a “sector weight” rating on shares of Simulations Plus in a report on Wednesday, October 29th. Citigroup reissued a “market perform” rating on shares of Simulations Plus in a report on Tuesday, January 6th. Finally, BTIG Research downgraded Simulations Plus from a “buy” rating to a “neutral” rating in a research report on Thursday, December 18th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $25.00.

Simulations Plus Profile

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.